Skip to content
DE

NafarelinIntranasal GnRH agonist

Nafarelin is a GnRH agonist delivered through the nose. With sustained exposure, it suppresses reproductive hormones, showing why the route of a medicine does not tell us how local its effects will be.

What is Nafarelin?

Nafarelin is a GnRH agonist delivered as a nasal medicine. It has been used for conditions including endometriosis and central precocious puberty, with indications depending on the product and country. 1 2

How it works

Although delivered through the nose, it acts systemically. Sustained GnRH stimulation downregulates pituitary signalling and reduces downstream sex-hormone production. 2

Effects studied

Endometriosis symptoms

Clinical research includes comparison with danazol in endometriosis. Findings from that setting do not answer every question about other hormone-dependent conditions.

Evidence: Disease-specific comparative trial. 1

What does the evidence show?

Endometriosis trial and manufacturer information leads

Absorption through the nose is only the beginning

Nafarelin enters the circulation through the nasal lining and acts on the pituitary GnRH receptor. Continuous stimulation eventually reduces LH and FSH release. That lowers downstream sex hormones, rather than creating a purely local effect in the nose.

The clinical purpose is condition-specific

Nafarelin has a clinical history in endometriosis and central precocious puberty, although product indications vary by country. In endometriosis, treatment concerns hormone-responsive symptoms and lesions. In central precocious puberty, it addresses early activation of puberty signalling. Evidence of benefit needs to be considered separately for each condition.

What the older comparison contributes

The retained endometriosis trial compared nafarelin with danazol. It helps describe effects under that study’s conditions, but it does not establish that the same choice is best against every current alternative. Symptom relief, recurrence, tolerability and treatment duration all influence the practical comparison. 1

Hormone effects and delivery both matter

Lower oestrogen can contribute to hot flushes and bone loss. Nasal symptoms and reliable administration also matter because they affect exposure. Assessing the spray means considering both its systemic endocrine effects and its practical use: avoiding injections does not make the treatment inherently mild. 2 3

Safety & status

Sex-hormone suppression can cause hot flushes and affect bone health. Nasal administration and absorption also introduce product-specific practical considerations. 2 3

Country and product status

Product indications and availability vary by country; current EU and Swiss status has not been independently checked for this draft.

Frequently asked questions

Does nasal delivery mean the effect stays in the nose?

No. The intended hormonal effect is systemic. 2

Is it suitable for indefinite symptom treatment?

Duration and monitoring are product- and diagnosis-specific, particularly because sex-hormone suppression can affect bone health. 2

Further reading

Concept illustration for Nafarelin.GuideNafarelin: how it works, what it is used for and side effectsNafarelin is a nasal spray used for endometriosis and central precocious puberty. How it works and which risks have been described.Read the article

Sources

This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.

  1. Retained paper reference Archive research lead · Retained archive reference; not independently checked for this draft
  2. Retained source reference Archive research lead · Retained archive reference; not independently checked for this draft
  3. Retained source reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance

This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.